...More than 100 million Africans are at risk of infection from the disease, Amazigo said. The drug, moxidectin, developed by Wyeth Pharmaceuticals, kills the larvae and adult worms of Onchocerca volvulus, which gives the disease its name. Moxidectin is to be...

... Today Asher Mullard Please Login to read the full article. Wyeth Pharmaceuticals has launched Phase III trials in three African countries to test reformulated animal antiparasitic moxidectin as a treatment for river blindness,...

...possible to help ensure that their independence and optimum quality of life is maintained." In the survey, developed by Wyeth Pharmaceuticals and supported by NRAS, simple activities which are normally taken for granted are shown to be significantly affected...

...that threatens 100 million people mostly in Africa. The phase three trial of the drug moxidectin, in collaboration with Wyeth Pharmaceuticals, would involve 1 500 people in Ghana, Liberia and the Democratic Republic of Congo, said the WHO. Also called onchocerciasis,...

...of newly issued shares (American Depositary Receipts – ADRs), which represents an 18.4% stake. Elan has been collaborating with Wyeth Pharmaceuticals (WYE) -- itself in a deal to be acquired by Pfizer (PFE) -- for the Alzheimer’s program. J&J will assume and...

...of the Special Programme for Research and Training in Tropical Diseases (TDR), which is administered by WHO, with Wyeth Pharmaceuticals. The work ranges from the development of a formulation for human use and initial studies in healthy volunteers, to clinical...

...and the Democratic Republic of Congo to test a remedy that could help stop transmission, according to drug manufacturer Wyeth Pharmaceuticals and the World Health Organization (WHO). Onchocerciasis transmitted through black flies that breed near rivers is...

... (AP)  Some of the significant cases the Supreme Court decided in its 2008-2009 term: REVERSE DISCRIMINATION The Supreme Court ruled 5-4 that white firefighters in New Haven, Conn., were unfairly denied promotions because of their race. It was a decision...

... The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In parti...

...Pa.-based Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE) said it will pay South San Francisco, Calif.-based Catalyst $21 million upfront. Total payments for research funding and milestones could exceed $500 million, the companies said. Wyeth Research...